{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T03:50:45Z","timestamp":1765079445107,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.pupt.2021.101999","type":"journal-article","created":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T01:45:42Z","timestamp":1612835142000},"page":"101999","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Risk factors associated with increased discontinuation rate of trimethoprim\u2013sulfamethoxazole used as a primary prophylaxis for Pneumocystis pneumonia: A retrospective cohort study"],"prefix":"10.1016","volume":"67","author":[{"given":"Toshihito","family":"Otani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9117-1934","authenticated-orcid":false,"given":"Kakuhiro","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinjiro","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Horimasu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0035-674X","authenticated-orcid":false,"given":"Taku","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4922-5334","authenticated-orcid":false,"given":"Hiroshi","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2474-9943","authenticated-orcid":false,"given":"Shintaro","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Fujitaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironobu","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noboru","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2021.101999_bib1","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.amjmed.2014.07.010","article-title":"Incidence of Pneumocystis jiroveci pneumonia among groups at risk in HIV-negative patients","volume":"127","author":"Fillatre","year":"2014","journal-title":"Am. J. Med."},{"key":"10.1016\/j.pupt.2021.101999_bib2","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1001\/jama.1992.03480060078034","article-title":"Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital","volume":"267","author":"Sepkowitz","year":"1992","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.pupt.2021.101999_bib3","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMra032588","article-title":"Pneumocystis pneumonia","volume":"350","author":"Thomas","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pupt.2021.101999_bib4","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3201\/eid1903.121151","article-title":"Increasing Pneumocystis pneumonia, England, UK, 2000-2010","volume":"19","author":"Maini","year":"2013","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.pupt.2021.101999_bib5","doi-asserted-by":"crossref","first-page":"R43","DOI":"10.1186\/ar4472","article-title":"Prophylaxis for Pneumocystis pneumonia in patients with rheumatoid arthritis treated with biologics, based on risk factors found in a retrospective study","volume":"16","author":"Katsuyama","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.pupt.2021.101999_bib6","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1378\/chest.113.5.1215","article-title":"Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia","volume":"113","author":"Pareja","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2021.101999_bib7","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1086\/339548","article-title":"Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome","volume":"34","author":"Sepkowitz","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.pupt.2021.101999_bib8","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1378\/chest.118.3.704","article-title":"Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states","volume":"118","author":"Mansharamani","year":"2000","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2021.101999_bib9","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJM199212243272603","article-title":"A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group","volume":"327","author":"Schneider","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pupt.2021.101999_bib10","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJM199812243392604","article-title":"Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group","volume":"339","author":"El-Sadr","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pupt.2021.101999_bib11","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199503163321101","article-title":"A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group","volume":"332","author":"Bozzette","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pupt.2021.101999_bib12","article-title":"Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients","volume":"2014","author":"Stern","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.pupt.2021.101999_bib13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13075-016-1206-8","article-title":"Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial","volume":"19","author":"Utsunomiya","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.pupt.2021.101999_bib14","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jiac.2019.01.005","article-title":"Efficacies of atovaquone, pentamidine, and trimethoprim\/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases","volume":"25","author":"Kitazawa","year":"2019","journal-title":"J. Infect. Chemother."},{"key":"10.1016\/j.pupt.2021.101999_bib15","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/S0025-6196(12)62478-1","article-title":"Trimethoprim-sulfamethoxazole","volume":"66","author":"Cockerill","year":"1991","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.pupt.2021.101999_bib16","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/j.1532-5415.1990.tb03459.x","article-title":"Antimicrobial therapy for the elderly patient","volume":"12","author":"Yoshikawa","year":"1990","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.pupt.2021.101999_bib17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1016\/j.pupt.2021.101999_bib18","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/bjc.1997.509","article-title":"Adjustment of creatinine clearance improves accuracy of Calvert's formula for carboplatin dosing","volume":"76","author":"Ando","year":"1997","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.pupt.2021.101999_bib19","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1378\/chest.06-1467","article-title":"Serum indicators for the diagnosis of Pneumocystis pneumonia","volume":"131","author":"Tasaka","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2021.101999_bib20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/2110-5820-4-13","article-title":"Cotrimoxazole - optimal dosing in the critically ill","volume":"4","author":"Brown","year":"2014","journal-title":"Ann. Intensive Care"},{"key":"10.1016\/j.pupt.2021.101999_bib21","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2169\/internalmedicine.42.665","article-title":"Hyponatremia and\/or hyperkalemia in patients treated with the standard dose of trimethoprim-sulfamethoxazole","volume":"42","author":"Mori","year":"2003","journal-title":"Intern. Med."},{"key":"10.1016\/j.pupt.2021.101999_bib22","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1128\/AAC.05037-11","article-title":"Influence of NAT2 polymorphisms on sulfamethoxazole pharmacokinetics in renal transplant recipients, Antimicrob","volume":"56","author":"Kagaya","year":"2012","journal-title":"Agents Chemother."},{"key":"10.1016\/j.pupt.2021.101999_bib23","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1001\/archinte.163.4.402","article-title":"Trimethoprim-sulfamethoxazole revisited","volume":"163","author":"Masters","year":"2003","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.pupt.2021.101999_bib24","article-title":"Multicenter study of trimethoprim\/sulfamethoxazole-related hepatotoxicity: incidence and associated factors among HIV-infected patients treated for Pneumocystis jirovecii pneumonia","volume":"9","author":"Yang","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.pupt.2021.101999_bib25","doi-asserted-by":"crossref","first-page":"R23","DOI":"10.1186\/ar2134","article-title":"Association of the diplotype configuration at the N-acetyltransferase 2 gene with adverse events with co-trimoxazole in Japanese patients with systemic lupus erythematosus","volume":"9","author":"Soejima","year":"2007","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.pupt.2021.101999_bib26","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01936-16","article-title":"Penetration of ciprofloxacin and amikacin into the alveolar epithelial lining fluid of rats with pulmonary fibrosis","volume":"61","author":"Ni","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pupt.2021.101999_bib27","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.pupt.2013.10.004","article-title":"Intrapulmonary concentration of levofloxacin in patients with idiopathic pulmonary fibrosis","volume":"28","author":"Huang","year":"2014","journal-title":"Pulm. Pharmacol. Therapeut."}],"container-title":["Pulmonary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553921000110?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553921000110?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T21:30:10Z","timestamp":1761082210000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553921000110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":27,"alternative-id":["S1094553921000110"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2021.101999","relation":{},"ISSN":["1094-5539"],"issn-type":[{"type":"print","value":"1094-5539"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk factors associated with increased discontinuation rate of trimethoprim\u2013sulfamethoxazole used as a primary prophylaxis for Pneumocystis pneumonia: A retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2021.101999","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101999"}}